Juvenile idiopathic arthritis(JIA)is the most common rheumatic disease of childhood,and juvenile idiopathic associated uveitis(JIA-U)is the most frequently noted extra-articular manifestation.JIA-U can present asympto...Juvenile idiopathic arthritis(JIA)is the most common rheumatic disease of childhood,and juvenile idiopathic associated uveitis(JIA-U)is the most frequently noted extra-articular manifestation.JIA-U can present asymptomatically and lead to ocular complications,so regular screening and monitoring are needed to prevent potentially sight-threatening sequelae.Topical glucocorticoids such as prednisolone acetate are usually the first line of treatment for anterior uveitis associated with JIA-U,but long-term use may be associated with cataract,ocular hypertension and glaucoma.Disease modifying anti-rheumatic drugs(DMARDs)such as methotrexate allow tapering of the corticosteroids to prevent long-term complications.Biologic therapies have been increasingly used as targeted therapies for JIA-U,particularly monoclonal antibodies targeting the proinflammatory cytokine TNF-αsuch as adalimumab and infliximab.One recent,multicenter,prospective,randomized clinical trial provided evidence of the efficacy of adalimumab with methotrexate for JIA-U compared to methotrexate alone.Another clinical trial studying the interleukin-6 inhibitor tocilizumab for JIA-U showed promise in tapering topical corticosteroids.Additionally,JAK inhibitors are emerging biologic therapies for JIA-U in patients refractory to TNF-αinhibitors,with a clinical trial assessing the efficacy of baricitinib for JIA-U underway.While clinical trials on these novel biologics are limited,further investigation of these agents may provide additional therapeutic options for JIA-U.展开更多
We report here a 17-year-old boy with a complicated presentation of undifferentiated juvenile idiopathic arthritis, vision-threatening uveitis and chronic recurrent multifocal osteomyelitis (CRMO) in the pelvis. His s...We report here a 17-year-old boy with a complicated presentation of undifferentiated juvenile idiopathic arthritis, vision-threatening uveitis and chronic recurrent multifocal osteomyelitis (CRMO) in the pelvis. His severe iritis needed subtenon injections and only responded to infliximab after failing multiple biologics. Unfortunately he later developed infliximab-associated psoriasis. A combination of infliximab and ustekinumab induced remission of his arthritis, osteomyelitis, uveitis and psoriasis without experiencing severe infections.展开更多
幼年特发性关节炎(juvenile idiopathic arthritis,JIA)是儿童时期常见的风湿免疫性疾病。幼年特发性关节炎相关葡萄膜炎(juvenile idiopathic arthritis-associated uveitis,JIA-U)是JIA重要的关节外并发症,主要表现为隐匿起病的虹膜...幼年特发性关节炎(juvenile idiopathic arthritis,JIA)是儿童时期常见的风湿免疫性疾病。幼年特发性关节炎相关葡萄膜炎(juvenile idiopathic arthritis-associated uveitis,JIA-U)是JIA重要的关节外并发症,主要表现为隐匿起病的虹膜和睫状体前部非肉芽肿性炎症(虹膜睫状体炎),是造成儿童时期残疾和失明的重要原因之一。近年来,美国风湿病学会(American College of Rheumatology,ACR)及欧洲儿科风湿病学的单一枢纽和接入点(Single Hub and Access Point for Pediatric Rheumatology in Europe,SHARE)先后均发表了JIA-U的临床指南,但我国尚缺乏诊疗相关指导性文件。为进一步加强该病的临床认知和诊疗规范,中华医学会儿科学分会免疫学组、中国儿童风湿免疫病联盟、国家儿童健康与疾病临床研究中心风湿免疫联盟联合眼科专家共同制定了《幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)》,在疾病筛查、诊断、治疗等方面达成初步共识,以供临床参考。展开更多
基金This project was supported by unrestricted departmental grant from Research to Prevent Blindness,Inc.to the Emory Eye Center,Emory University School of Medicine,National Eye Institute/National Institutes of Health core grant P30-EY06360(Department of Ophthalmology,Emory University School of Medicine)National Eye Institute of the National Institutes of Health under award number K23 EY030158(Shantha),R01EY030521(STAH),and R01 EY029594(SY)The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the views or policies of the Department of Health and Human Services,nor does mention of trade names,commercial products,or organizations imply endorsement by the U.S.Government.
文摘Juvenile idiopathic arthritis(JIA)is the most common rheumatic disease of childhood,and juvenile idiopathic associated uveitis(JIA-U)is the most frequently noted extra-articular manifestation.JIA-U can present asymptomatically and lead to ocular complications,so regular screening and monitoring are needed to prevent potentially sight-threatening sequelae.Topical glucocorticoids such as prednisolone acetate are usually the first line of treatment for anterior uveitis associated with JIA-U,but long-term use may be associated with cataract,ocular hypertension and glaucoma.Disease modifying anti-rheumatic drugs(DMARDs)such as methotrexate allow tapering of the corticosteroids to prevent long-term complications.Biologic therapies have been increasingly used as targeted therapies for JIA-U,particularly monoclonal antibodies targeting the proinflammatory cytokine TNF-αsuch as adalimumab and infliximab.One recent,multicenter,prospective,randomized clinical trial provided evidence of the efficacy of adalimumab with methotrexate for JIA-U compared to methotrexate alone.Another clinical trial studying the interleukin-6 inhibitor tocilizumab for JIA-U showed promise in tapering topical corticosteroids.Additionally,JAK inhibitors are emerging biologic therapies for JIA-U in patients refractory to TNF-αinhibitors,with a clinical trial assessing the efficacy of baricitinib for JIA-U underway.While clinical trials on these novel biologics are limited,further investigation of these agents may provide additional therapeutic options for JIA-U.
文摘We report here a 17-year-old boy with a complicated presentation of undifferentiated juvenile idiopathic arthritis, vision-threatening uveitis and chronic recurrent multifocal osteomyelitis (CRMO) in the pelvis. His severe iritis needed subtenon injections and only responded to infliximab after failing multiple biologics. Unfortunately he later developed infliximab-associated psoriasis. A combination of infliximab and ustekinumab induced remission of his arthritis, osteomyelitis, uveitis and psoriasis without experiencing severe infections.
文摘幼年特发性关节炎(juvenile idiopathic arthritis,JIA)是儿童时期常见的风湿免疫性疾病。幼年特发性关节炎相关葡萄膜炎(juvenile idiopathic arthritis-associated uveitis,JIA-U)是JIA重要的关节外并发症,主要表现为隐匿起病的虹膜和睫状体前部非肉芽肿性炎症(虹膜睫状体炎),是造成儿童时期残疾和失明的重要原因之一。近年来,美国风湿病学会(American College of Rheumatology,ACR)及欧洲儿科风湿病学的单一枢纽和接入点(Single Hub and Access Point for Pediatric Rheumatology in Europe,SHARE)先后均发表了JIA-U的临床指南,但我国尚缺乏诊疗相关指导性文件。为进一步加强该病的临床认知和诊疗规范,中华医学会儿科学分会免疫学组、中国儿童风湿免疫病联盟、国家儿童健康与疾病临床研究中心风湿免疫联盟联合眼科专家共同制定了《幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)》,在疾病筛查、诊断、治疗等方面达成初步共识,以供临床参考。
